Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Products under Development by Stage of Development | 8 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Products under Development by Therapy Area | 9 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Products under Development by Indication | 10 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Products under Development by Companies | 13 | 2 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Therapeutics Assessment | 15 | 5 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Companies Involved in Therapeutics Development | 20 | 8 |
| BioCrea GmbH | 20 | 1 |
| Bristol-Myers Squibb Company | 21 | 1 |
| Cerecor Inc. | 22 | 1 |
| Johnson &Johnson | 23 | 1 |
| Luc Therapeutics, Inc. | 24 | 1 |
| NeurOp, Inc | 25 | 1 |
| Novartis AG | 26 | 1 |
| UCB S.A. | 27 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Drug Profiles | 28 | 14 |
| CERC-301 Drug Profile | 28 | 2 |
| EVT-100 Series Drug Profile | 30 | 1 |
| EVT-103 Drug Profile | 31 | 2 |
| NP-10679 Drug Profile | 33 | 2 |
| NP-11948 Drug Profile | 35 | 1 |
| radiprodil Drug Profile | 36 | 2 |
| Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia Drug Profile | 38 | 1 |
| Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder Drug Profile | 39 | 1 |
| Small Molecules to Antagonize NR2B for Depression Drug Profile | 40 | 1 |
| Small Molecules to Antagonize NR2B for Neuropathic Pain Drug Profile | 41 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Dormant Projects | 42 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Discontinued Products | 43 | 1 |
| Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Featured News &Press Releases | 44 | 7 |
| Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model | 44 | 1 |
| Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect | 44 | 1 |
| Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder | 44 | 1 |
| Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum | 45 | 1 |
| Oct 02, 2014: NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Receptor Compound as Drug Development Candidate | 45 | 1 |
| Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigational MDD Study | 46 | 1 |
| Nov 25, 2013: Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder | 46 | 1 |
| Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate | 47 | 1 |
| Jun 28, 2010: Forest And Gedeon Richter Announce Phase II Study Results Of Radiprodil For Treatment Of Diabetic Peripheral Neuropathic Pain | 48 | 1 |
| Mar 11, 2010: Evotec Completes Clinical Part Of First Phase I Study Of EVT 103 | 48 | 1 |
| Sep 08, 2009: Evotec Starts Phase I With EVT 103, An NR2B-Selective NMDA Receptor Antagonist | 49 | 1 |
| Nov 29, 2005: Gedeon Richter And Forest Laboratories Expand Relationship With Two New Collaborations For CNS Compounds | 49 | 1 |
| Mar 24, 2004: Evotec Neurosciences License NMDA Receptor NR2B Subunit Selective Antagonists From Roche | 50 | 1 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |